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Abstract: The molecular structure of acetylcholinesterase (AChE) attracts interest because of its versatility and significant role in the
cholinergic system. The main purpose of the present study was to clone a full-length cDNA sequence of human brain acetylcholinesterase
(hAChE) into pET SUMO vector and express it successfully. The integrity of the constructed plasmid was confirmed by cross PCR. This
recombinant construct was expressed in Escherichia coli BL21 (DE-3). In this work, we produced hexahistidine (6xHis) tagged fusion
protein by isopropyl β-D-1-thiogalactopyranoside (IPTG) induction and purified using nickel (Ni2+) affinity chromatography. Using
anti-His antibody, we detected ~90 kDa fusion protein. The expression of the hAChE gene in a microbial host resulted in good biological
activity. Using the Ellman method, the recombinant AChE exhibited activity with optima at pH 9.0 glycine–NaOH buffer and room
temperature. Kinetic parameters, KM and Vmax, were determined as 0.63 and 0.69, respectively.
Key words: Acetylcholinesterase, cloning, recombinant protein, enzyme characterization

1. Introduction
Characteristic of cholinergic synapses is termination of
synaptic transmission by neurotransmitter hydrolysis
(Zimmerman and Soreq, 2006). Acetylcholinesterase
(AChE) is present at all cholinergic synapses and exerts
an essential role in cholinergic transmission by swiftly
hydrolyzing the acetylcholine that is a key component of
cholinergic signaling. This function of enzyme depends on
two main features: its extraordinary processing speed and
its specific localization in synaptic clefts (Bernard et al.,
2011; Lee et al., 2012).
Recent studies suggest that termination of transmission
is just one of the many roles of AChE. In addition to its
cholinesterase activity, the enzyme is also involved in
apoptosis, microtubule formation, inflammation, stress
response, and cell proliferation/differentiation (Layer and
Willbold, 1995; Small et al., 1996; Soreq and Seidman,
2001; Pick et al., 2006; Shaked et al., 2009). The enzyme
can be found in multiple forms in various developmental
stages, tissues, or cell types such as erythrocytes, nerve
endings, human fibroblasts, osteoblasts, spleen, lung, rat
kidney, and leukocytes (Inkson et al., 2004; Patocka et
al., 2004; Thiermann et al., 2007) but essentially exists
in most regions of the central and peripheral nervous
system (Tripathi and Srivastava, 2008; Shaked et al., 2009;
Silverman et al., 2014). This distinct localization ability of
* Correspondence: oerdogan@atauni.edu.tr

enzyme may occur because diverse AChE molecular forms
are generated by sequential regulation of AChE pre-mRNA
(Li et al., 1993; Chan et al., 1999; Shapira et al., 2000). These
versatile features and functions of the enzyme, especially
in cholinergic traffic, also make it a potential multitarget
for Alzheimer disease (AD) treatment candidate drugs
(Du and Carlier, 2004; Colovic et al., 2013).
Current therapeutic strategies for AD focus on
increasing acetylcholine (ACh) bioavailability at the
synapse. Therefore, revealing enzyme response against
therapeutic agents that alter AChE activity is extremely
important for orienting treatment strategies (Singh et
al., 2013). Nowadays, protein-based therapeutics are
approved for clinical use and many new products are
launched each year because of their significant advantages
such as enhanced efficacy, greater safety, and reduced
immunogenicity (Carter, 2011). As well as the clinical use,
the production of a protein by recombinant methods is
quite important in terms of clarification of the structural
and biochemical properties of the enzyme (Kawai et al.,
2003).
Proteins have many different structures in their
physiochemical properties. Thus, production of a protein
is quite an arduous task. In the case of use of prokaryotes
as a host organism, fusion partners can help to overcome
these obstacles and can be used an efficient approach
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to improve the yield of targeted proteins expressed in E.
coli (Esposito and Chatterjee, 2006; Hayashi and Kojima,
2010; Zhou et al., 2015). It well known that many small
molecules such as ubiquitin exert chemical chaperoning
effects on fused proteins (Malakhov et al., 2004). As a result
of this action, attachment of SUMO (small ubiquitin-like
modifier) or ubiquitin to the N-terminus of a partner
protein, recombinant fusion proteins are dramatically
increased (Panavas et al., 2009; Wang et al., 2010). SUMO
is a modifier protein consisting of approximately a
hundred amino acids and is reversible attached to target
proteins and absent in prokaryotes (Seeler and Dejean,
2003; Johnson, 2004). This attachment changes the
stability, function, and/or localization as a consequence
of changing of the protein structure (Wang et al., 2008;
Panavas et al., 2009).
Consequently, it might alter interactions between
DNA and other DNA-bound protein complexes, causing
the transcription factors accessibility to genetic material
(Eilebrecht et al., 2010). Because of SUMO conjugation
consequences that vary from substrate to substrate,
functional mechanisms of this attachment are not fully
resolved at the molecular level (Johnson, 2004). To date,
SUMO fusion tags were successfully used in various
difficult-to-express proteins’ production with improved
yield and solubility (Malakhov et al., 2004; Zuo et al., 2005;
Marblestone et al., 2006).
In the present work, we introduced the use of pETSUMO recombinant plasmid to express AChE. We
optimized the conditions required for AChE expression
and obtained the enzyme with high activity after simple
purification. Beyond that, the AChE was characterized
biochemically. This study provides a promising method for
the simple, swift, and effective production of recombinant
human acetylcholinesterase for use in drug development
and in understanding and unravelling biochemical
conduct against therapeutics.
2. Materials and methods
2.1. Bacterial strains, plasmids, medium and reagents
E. coli One Shot Mach1-T1R chemically competent cells
were used for the transformation of vectors and E. coli
BL21 (DE3) One Shot was used as a host strain for protein
expression. The pET SUMO vector (Invitrogen) was used
for T-A cloning and protein expression. All other analytical
grade chemicals were obtained from Sigma (Germany).
2.2. Plasmid construction and cloning of AChE
Adult human brain cDNA was purchased from
Invitrogen (USA). In order to produce recombinant
protein in prokaryote expression systems, the coding
sequence of human AChE (GenBank accession number
M55040.1) was cloned into the pET SUMO expression
vector (Invitrogen). The coding sequence of the target
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gene was amplified by PCR using the forward primer
5’-ATGAGGCCCCCGCAGTGTCT-3’ and the reverse
primer 5’-TCACAGGTCTGAGCAGCGATCC-3’. The
PCR protocol was as follows: after the first denaturation
step at 94 °C for 4 min, followed by 35 cycles of 2.5 min at
94 °C, 30 s at 66 °C, and 2 min at 72 °C a final extension for
5 min at 72 °C was added at the end of this reaction. Using
a GeneJET Gel Extraction Kit (Thermo Scientific), 1845 bp
PCR product was purified from agarose gel. This fragment
was cloned into the pET SUMO vector (Figure 1). All steps
were done according to the manufacturer’s instructions.
2.3. Recombinant protein expression
The generated construct encoded a 645 amino acid
recombinant protein. The N-terminal of its sequence
contained a 6xHis tag. Component E. coli One Shot MachT1R cells treated with ligation mixture were grown overnight
at 37 °C in LB plates (1% tryptone, 0.5% NaCl, 0.5% yeast
extract, and 2% agar) containing 50 µg/mL kanamycin. The
presence of the DNA insert was determined by screening
colonies using colony PCR. To determine the insert, four
combinations (gene–gene, vector–vector, gene forward–
vector reverse, and gene reverse–vector forward) of vector
specific and insert specific primers were used. Plasmid
purification was performed from desired clones using a
GeneJET Plasmid Miniprep Kit (Thermo).
Plasmids were transformed into E. coli BL21(DE3)
using the classic heat shock method and grown in LB
plates. Preculture was prepared as follows: a single colony
from the agar plate was inoculated into 10 mL of LB
medium and grown at 37 °C and 170 rpm overnight.
For production of 6xHis fusion protein, 1 mL of the
preculture was added to 200 mL of 50 µg/mL kanamycin
and 1% glucose containing LB medium. IPTG was added
when OD600 reached approximately 0.4~0.6 and then the
medium was incubated at 180 rpm and 37 °C.

Figure 1. Schematic overview depicting the construction of the
prokaryotic expression vector pET-SUMO.
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2.4. Protein purification
After induction, cells were harvested by centrifugation at
3000 for 5 min. Cell pellets were re-suspended in 1 mL
of lysis buffer (50 mM potassium phosphate, pH 7.8, 400
mM NaCl, 100 mM KCl, 10% glycerol, 0.5% Triton X-100,
and 10 mM imidazole). Cell suspension was disrupted
again by three freeze–thaw cycles using liquid nitrogen
and a 42 °C water bath after the sonication step. The lysate
was centrifuged at 12,000 rpm for 1 min. Supernatant was
transferred to a fresh tube. Protein was concentrated to 30fold and recovered with an Amicon Filter (Merck Millipore).
Using a ProBond Ni-NTA resin column (Invitrogen) the
filtrate obtained from cell homogenate was purified. For
purification soluble concentrated filtrate was incubated
with Ni–NTA resin (2 mL) equilibrated in native binding
buffer and allowed to bind to the Probond affinity column
for 30–60 min at room temperature. All untagged proteins
were allowed to pass through the column using pH 8 wash
buffer (50 mM NaH2PO4, 20 mM imidazole, and 0.5 M
NaCl). Using pH 8 elution buffer (0.5 M NaCl, 250 mM
imidazole, and 50 mM NaH2PO4) the bound proteins were
recovered from the column. This fraction was dialyzed
twice against a buffer (20 mM Na2HPO4, pH 8) at 4 °C for
2 h. The final sample was stored ice cold and then used for
Bradford protein quantification, western blot, SDS-PAGE
analysis, and enzyme activity assays.
2.5. Protein analysis
The protein concentration was determined by Bradford
assay (Bradford, 1976) using bovine serum albumin as
the standard protein. Absorbance was read at 595 nm.
Assessment of AChE activity was performed using Ellman’s
assay (Ellman et al., 1961). Time dependent expression
level, purity, and molecular mass of the recombinant
protein were determined by SDS-PAGE (12%). The
exact size of fusion protein was determined by western
blot analysis using Anti-HisG Antibody (Invitrogen).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as loading control.
2.6. Characterization of purified enzyme
Effect of pH on enzyme activity was measured using the
following various buffers: sodium phosphate (pH 5.5–8),
Tris-HCl (pH 7.5–9) and glycine–NaOH (pH 9–10.5). To
determine optimal pH and buffer concentration for ionic
strength, the enzyme activity was measured using different
concentrations (ranging from 50 mM to 1 M) of glycine–
NaOH buffer. Enzyme activity was assayed at various
temperatures from 4 °C to 90 °C for determining optimum
temperature. In order to determine KM and Vmax values,
acetylcholine iodide was used as a substrate with different
concentrations.

3. Results
3.1. Construction and validation of recombinant pETSUMO-hrAChE vector
Recombinant vector was constructed as described in the
methods. After amplification and purification (Figure 2) of
the target protein gene sequence, full-length hAChE was
ligated and cloned into pET-SUMO vector. Colony and
cross PCR results (Figures 3A and 3B) showed that the
gene inserted correctly into pET-SUMO vector. The length
of amplified products was consistent with theoretical
expectations (Table 1).
3.2. Expression of rAChE
The hAChE protein was expressed in E. coli as a His-tagged
protein. For the production of recombinant protein, a
single clone of E. coli BL21 (DE3) harboring the vector
was used. After IPTG induction, cells were harvested by
three cycles of rapid freeze (liquid nitrogen) and thaw
(42 °C water bath). Cell lysate was analyzed by SDSPAGE. Approximately 90 kDa fusion protein appeared
as expected (data not shown). According to this result,
optimal expression conditions were adopted as 37 °C for 7
hours by 1 mM IPTG (Figure 4).
3.3. Purification and identification of target protein
Purified and dialyzed hAChE was firstly determined by the
Bradford assay. Bradford results (Table 2) show that IPTG
induction and concentration experiments significantly
affected protein yielding. For verification of the target
protein, western blot analysis was performed using an
Anti-HisG antibody. 6xHis tag fusion protein with ~90
kDa molecular weight was recognized (Figure 5).
3.4. Determination of kinetic constants
The recombinant purified AChE was utilized to determine
the kinetic characteristics of the enzyme. The optimum
pH for recombinant enzyme activity was observed in
glycine–NaOH (pH 9) buffer. Activity was observed
at the maximum rate at this pH (Figure 6). In order to
determine the effect of ionic strength on the enzyme
activity, measurements were performed using different
concentrations (between 0.05 and 1.5 M) of glycine–
NaOH buffer. Maximum enzyme activity was observed in
1 M (pH 9) glycine–NaOH buffer (Figure 7).
In order to determine the optimal temperature for
maximum rhAChE activity efficiency, enzyme activity
was measured between 0 and 90 °C. According to the
results, room temperature was considered the optimum
temperature for enzymatic activity. However, enzyme
activity decreased drastically at excessively high and low
temperatures. Activity completely ceased at 90 °C (Figure
8).
KM and Vmax were determined by Lineweaver–Burk
analysis using acetylcholine iodide (Figure 9). Kinetic
constants were calculated by assaying enzyme activity
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Figure 2. Electrophoresis of PCR products for AChE on 1% agarose gel electrophoresis.

as previously described by varying the concentrations of
substrate from 0.05 to 0.35 mM. Obtained results for KM
and Vmax were 0.63 mM and 0.69 EU/mL, respectively.
4. Discussion
The most commonly reported expression systems are still
prokaryotic or mammalian-cell based (Sørensen, 2010).
Each system offers specific properties. The advantages and
disadvantages of different expression systems are shown in
Table 3. For achieving production of recombinant protein
with high quality, there should be compatibility between
the host and the desired protein (Costa et al., 2014). Today,
efficient strategies for the generation of recombinantly
expressed proteins are focused on obtaining production
in the least possible time and at the lowest cost. Producing
large amounts of recombinant proteins rapidly, efficiently,
and economically often requires the use of bacterial host
organisms because of their priceless characteristics such as
ability to grow quickly, availability of a wide variety of mutant
strains, well-known genome, and inexpensive requirements
for optimal conditions (Swartz, 2001; Terpe, 2006).
Proteins are commonly used biomolecules in scientific
research and in medical and industrial areas. However, it
is well known that removal of these molecules from their
natural environment is a very difficult and expensive
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process. Another important problem in this regard is
the contamination risk of proteins with disease-causing
agents (Houdebine, 2000; Swartz, 2001; Ma et al., 2003).
Recombinantly produced proteins are very close to their
natural state; thus they can have various features compared
with nonrecombinants such as they can be used without
triggering an immune rejection, there is no contamination
risk with human or animal disease agents because they
are obtained using isolated hosts, and their activities
are alterable using molecular techniques (Demain
and Vaishnav, 2009; Dolinska et al., 2014). Besides
the advantages mentioned above there are also some
restrictions. The most important hallmark or unwanted
phenomenon in production of recombinant eukaryotic
proteins using prokaryotic hosts is posttranslational
modifications (Kamionka, 2011) such as glycosylation,
proteolytic maturation, and disulfide bond formation.
Glycosylation is one of the major types and common
forms of protein modifications in nature (Chan et al.,
2012), and can affect the biological activity, stability, and
transports of proteins (Helenius and Aebi, 2001; Solá
and Griebenow, 2009). Cholinesterase sequences have
individual putative glycosylation signals. However, the
location and number of these signals are not well conserved
along the family members. Human, rat, and mouse AChEs
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Figure 3A. Amplification products of recombinant pET-SUMO vector transformed
cells using AChE primers (1–8: selected colonies).

Figure 3B. Cross PCR analysis of purified recombinant pET-SUMO vector (1, 2; vector
reverse and forward primers, 3, 4; gene forward and vector reverse primers, 5, 6; gene
reverse and vector forward primers, 7, 8; gene primers).

display three glycosylation sites and these three sites are
well conserved in all mammalians (Soreq et al., 1990).
Previous mutagenesis studies have shown that elimination
of N-glycosylation had no effect on catalytic activity and
peripheral site functions of recombinant human AChE

(Velan et al., 1993; Chen et al., 2011a). In contrast to
catalytic activity and the assembly of AChE, glycosylation
is required for membrane trafficking (Chen et al., 2011b).
When considered in this regard, the use of E. coli seems to
be compatible for recombinant hAChE production.
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Table 1. PCR product sizes for different combinations.
Reaction

Template DNA

Forward Primer

Reverse Primer

Size (bp)

1

Recombinant plasmid

Vector

Vector

2103

2

Recombinant plasmid

Gene

Vector

1998

3

Recombinant plasmid

Vector

Gene

1950

4

Recombinant plasmid

Gene

Gene

1845

Figure 4. SDS-PAGE analysis of hAChE pilot expression at different harvesting times.
Table 2. Yielding comparisons of recombinant protein.
Sample

Expression lysate (mL)

A595

Yield (mg/mL)

Normal medium (uninduced)

100

0.171

18.6

Induced medium lysate

100

0.547

59.4

Induced medium concentrated filtrate

100

1.755

190.8

Concentrated filtrate dialysis

100

0.426

46.3

As we know, the production of native and recombinant
proteins in a well-characterized, purified, and biologically
active form has become a main goal for many sectors such
as the drug, agricultural, and biopharmaceutical industries
(Schmidt, 2004; Demain and Vaishnav, 2009). This field
not only intends to generate biologically active protein but
also seeks to achieve high-throughput (quality, time scale,
quantity etc.) production (Sanden et al., 2003; Correa and
Oppezzo, 2011). In addition, another major objective of
these companies or research groups is to develop new
and efficient approaches for generating large quantities
of recombinantly produced proteins. To improve these
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parameters, it is possible to use expression partners (also
known as affinity tags or fusion tags) in E. coli. Moreover,
these tags can also bring additional properties such as
protection from degradation, improvement of affinity for
recoveries of proteins, and solubility (Costa et al., 2014).
For nearly four decades, fusion tags have been widely
used in protein overproduction (Majorek et al., 2014).
Polyhistidine tags are especially suited for target protein
production with minimal perturbation. In some cases, as
we observed, the tag may interfere with enzyme activity
(Freydank et al., 2008; Panek et al., 2013). However,
generally produced fusion proteins are as active as wild-

CEYLAN and ERDOĞAN / Turk J Biol

Figure 5. Western blotting and ImageJ relative intensity ratio analysis of
recombinantly produced hAChE using antiHis-tag antibody. GAPDH was
used as loading control. M; protein molecular size marker, Lane 1; Negative
control (uninduced), Lane 2; Transformed BL21(DE3) cells 7 h after 1 mM
IPTG induction.

type ones (Guergova-Kuras et al., 1999; Job et al., 2002).
When comparing our results with those of a previous study
(Fischer et al., 1993) kinetic constants appear relatively
high but product quantity obtained was better than in
the mentioned paper. The observed relatively low affinity
of rhAChE to acetylcholine iodide (substrate) may be a
result of undesirable changes in protein structure caused
by uncleaved 6xHis-SUMO tag (Terpe, 2003).

In this work, we obtained a stable recombinant human
AChE that was enough to allow kinetic studies from the
brain after cloning and expressing with SUMO partner.
Recombinant and biologically active enzyme was removed
and purified from the pellet fraction of cell lysate. As
we mentioned above, the SUMO system is superior for
problematic protein expression when compared with
other commonly used fusion tags. Another reason for
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Figure 6. Optimum pH. The reaction was carried out in the following buffers: sodium
phosphate (pH 5.5–8), Tris-HCl (pH 7.5–9), and glycine–NaOH (pH 9–10.5).
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Table 3. Comparison of different expression hosts for protein production (Ma et al., 2003).
System

Cost

Production
time

Scale-up
capacity

Product
quality

Contamination risks

Storage cost

Bacteria

Low

short

High

Low

Endotoxins

Moderate

Yeast

Medium

Medium

High

Medium

Low

Moderate

Mammalian cell

High

Long

Very low

Very high

Viruses, prions, and oncogenic DNA

Expensive

Transgenic animals

High

Very long

Low

Very high

Viruses, prions, and oncogenic DNA

Expensive

Plant cell

Medium

Medium

Medium

High

Low

Moderate

Transgenic plants

Very low

Long

Very high

High

Low

Inexpensive

preferring this technique is the substrate specificity of
SUMO protease. Specific N-terminus amino acids are
necessary for biological activity, half-life, and stability of
numerous therapeutic proteins. This protease recognizes a
specific site that acts as the target for cleavage and does not
cleave erroneously.
In summary, advantageous features of this fusion
system, which has advanced beyond the others, such
as using a single vector, rapid cloning of any gene

without restriction digestion, high-level expression,
affinity tagging methodology, and tag removal make it
useful. Taken together, our findings suggest that His tag
SUMO expression system is a rapid and efficient way to
produce human AChE and is useful for further studies
in order to observe the effect of some chemicals and/or
biological components on enzyme activity or structural
modifications.
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